Oneview Healthcare (ONE) H2 2025 earnings summary

Executive summary

• Achieved 21% year-over-year revenue growth in 2025, driven by new customer deployments, 18 new logos over three years, and strong U.S. market momentum.

• Major product innovation with the Ovie AI-powered digital care assistant suite and new user interface, accelerating operational efficiency and patient experience.

• Michael Dowling, CEO of New York's largest health system, joined the board, bringing significant industry expertise.

• Strategic partnership and integration with Baxter, including addition to a group purchasing organization of a top-10 U.S. health system, expanding addressable market.

Financial highlights

• Total revenue reached €12.0m, up 21% from €9.9m in 2024; recurring revenue grew 7% to €7.7m.

• Gross margin declined by 3 percentage points to 64% due to a higher mix of non-recurring revenue.

• Operating EBITDA loss reduced by 8% to €8.1m, reflecting higher revenue and lower H2 spend.

• Cash OpEx in H2 2025 was 9% lower than H1 2025 and 13% lower than H2 2024; cash used in operations reduced by 20% year-over-year.

• Cash position at year-end was €4.6m, with inventory of €2.9m in proprietary hardware.

Outlook and guidance

• Targeting a 20% increase in live endpoints by end of 2026, aiming for just under 18,000 endpoints and efficient 90-day deployments.

• Forecasting further OpEx reductions in 2026, with annualized savings of over €1.4m from H2 2025 cost actions.

• Gross margin expected to remain in the mid- to low-60s in 2026 due to revenue mix.

• New user experience and Ovie ecosystem to be delivered in H2 2026.

• Continued focus on driving efficiencies and accelerating deployment timelines with AI-enabled tools.